- Home
- HUHU vs SLS Comparison
HUHU vs SLS Comparison
Compare HUHU & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUHU
- SLS
- Stock Information
- Founded
- HUHU 2015
- SLS 2012
- Country
- HUHU China
- SLS United States
- Employees
- HUHU N/A
- SLS N/A
- Industry
- HUHU
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- HUHU
- SLS Health Care
- Exchange
- HUHU NYSE
- SLS Nasdaq
- Market Cap
- HUHU 91.5M
- SLS 89.6M
- IPO Year
- HUHU 2024
- SLS N/A
- Fundamental
- Price
- HUHU $4.34
- SLS $1.09
- Analyst Decision
- HUHU
- SLS
- Analyst Count
- HUHU 0
- SLS 0
- Target Price
- HUHU N/A
- SLS N/A
- AVG Volume (30 Days)
- HUHU 135.6K
- SLS 815.8K
- Earning Date
- HUHU 02-22-2025
- SLS 03-20-2025
- Dividend Yield
- HUHU N/A
- SLS N/A
- EPS Growth
- HUHU 13.14
- SLS N/A
- EPS
- HUHU 0.08
- SLS N/A
- Revenue
- HUHU $17,492,735.00
- SLS N/A
- Revenue This Year
- HUHU N/A
- SLS N/A
- Revenue Next Year
- HUHU N/A
- SLS N/A
- P/E Ratio
- HUHU $50.55
- SLS N/A
- Revenue Growth
- HUHU 33.03
- SLS N/A
- 52 Week Low
- HUHU $2.97
- SLS $0.77
- 52 Week High
- HUHU $9.89
- SLS $1.84
- Technical
- Relative Strength Index (RSI)
- HUHU N/A
- SLS 40.56
- Support Level
- HUHU N/A
- SLS $1.13
- Resistance Level
- HUHU N/A
- SLS $1.25
- Average True Range (ATR)
- HUHU 0.00
- SLS 0.07
- MACD
- HUHU 0.00
- SLS -0.01
- Stochastic Oscillator
- HUHU 0.00
- SLS 17.39
About HUHU HUHUTECH INTL GROUP INC
HUHUTECH International Group Inc specializes in providing factory facility management and monitoring systems, including high-purity gas, chemicals and liquid system and factory management and control systems for industrial clients, who are mainly semi-conductor manufacturers and electronics manufacturers in China. The products and services are widely used by semi-conductor manufacturers, LED and micro-electronics factories, as well as some pharmaceutical, food and beverage manufacturers.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.